Recombinant
RabMAb

Anti-Cytochrome P450 2D6 antibody [EPR17868] (ab185625)

Overview

  • Product name
    Anti-Cytochrome P450 2D6 antibody [EPR17868]
    See all Cytochrome P450 2D6 primary antibodies
  • Description
    Rabbit monoclonal [EPR17868] to Cytochrome P450 2D6
  • Tested applications
    Suitable for: WB, IHC-P, Flow Cyt, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human Cytochrome P450 2D6 aa 300 to the C-terminus. The exact sequence is proprietary.
    Database link: P10635

  • Positive control
    • WB: Cytochrome P450 2D6 transfected 293T lysate; Human fetal liver lysate; HeLa, K562, HepG2 and HT-29 whole cell lysates. IHC-P: Human liver, kidney and hepatocellular carcinoma tissues. ICC/IF: HT-29 cells. Flow Cyt: HT-29 cells.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab185625 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 55, 50 kDa (predicted molecular weight: 55, 50 kDa).
IHC-P 1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Flow Cyt 1/300. ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
ICC/IF 1/1000.

Target

  • Relevance
    Cytochrome P450 2D6 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 20% of commonly prescribed drugs. Its substrates include debrisoquine, an adrenergic-blocking drug; sparteine and propafenone, both anti-arrythmic drugs; and amitryptiline, an anti-depressant. The gene is highly polymorphic in the population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Cytochrome P450 2D6 is the molecular target of autoantibodies against the "liver kidney microsomal antigen 1" (LKM 1).
  • Cellular localization
    Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
  • Database links
  • Alternative names
    • CPD6 antibody
    • CYP2D antibody
    • CYP2D6 antibody
    • CYP2D7AP antibody
    • CYP2D7BP antibody
    • CYP2D7P2 antibody
    • CYP2D8P2 antibody
    • CYP2DL1 antibody
    • CYPIID6 antibody
    • Cytochrome P450 DB1 antibody
    • Cytochrome P450 family 2 subfamily D member 6 antibody
    • Cytochrome P450 family 2 subfamily D polypeptide 6 antibody
    • Debrisoquine 4 hydroxylase antibody
    • Flavoprotein linked monooxygenase antibody
    • Microsomal monooxygenase antibody
    • P450 DB1 antibody
    • P450C2D antibody
    • P450DB1 antibody
    • Xenobiotic monooxygenase antibody
    see all

Images

  • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HT-29 (Human colorectal adenocarcinoma cells) cells labeling Cytochrome P450 2D6 with ab185625 at 1/1000 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/400 dilution (green). Cytoplasmic staining on HT-29 cell line is observed. The nuclear counter stain is DAPI (blue). Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/500 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
    The negative controls are as follows:
    -ve control 1: ab185625 at 1/1000 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
    -ve control 2: ab7291 (anti-Tubulin mouse mAb) at 1/500 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/400 dilution.

     

  • Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Cytochrome P450 2D6 with ab185625 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human liver is observed. Counter stained with Hematoxylin.

    Negative control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling Cytochrome P450 2D6 with ab185625 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human kidney is observed. Counter stained with Hematoxylin.

    Negative control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human hepatocellular carcinoma tissue labeling Cytochrome P450 2D6 with ab185625 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human hepatocellular carcinoma is observed. Counter stained with Hematoxylin.

    Negative control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Flow cytometric analysis of 2% paraformaldehyde-fixed HT-29 (Human colorectal adenocarcinoma cells) cells labeling Cytochrome P450 2D6 with ab185625 at 1/300 dilution (red) compared with a rabbit monoclonal IgG isotype control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.

  • All lanes : Anti-Cytochrome P450 2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution

    Lane 1 : Full-length Cytochrome P450 2D6 transfected 293T lysate
    Lane 2 : Non-transfected 293T lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 55, 50 kDa
    Observed band size : 81 kDa (why is the actual band size different from the predicted?)

    Blocking/Dilution buffer: 5% NFDM/TBST.

     

    Full-length Cytochrome P450 2D6 293T overexpressed lysates contain GFP tagged-aa1-497.

  • Anti-Cytochrome P450 2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution + Human fetal liver lysate at 20 µg

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 55, 50 kDa
    Observed band size : 50,55 kDa

    Blocking/Dilution buffer: 5% NFDM/TBST.

    Based on the sequence analysis, ab185625 recognizes two isoforms with the predicted MWs of 55kDa and 50kDa respectively.

  • All lanes : Anti-Cytochrome P450 2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution

    Lane 1 : HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate
    Lane 2 : K562 (Human chronic myelogenous leukemia cells from bone marrow) whole cell lysate
    Lane 3 : HepG2 (Human liver hepatocellular carcinoma) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 55, 50 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)

    Blocking/Dilution buffer: 5% NFDM/TBST.

  • Anti-Cytochrome P450 2D6 antibody [EPR17868] (ab185625) at 1/1000 dilution + HT-29 (Human colorectal adenocarcinoma cells) whole cell lysate at 10 µg

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 55, 50 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)

    Blocking/Dilution buffer: 5% NFDM/TBST.

References

ab185625 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab185625.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up